德戈替尼(Delgocitinib) - 药物靶点：JAK1 x JAK2 x JAK3 x TYK2_在研适应症：慢性湿疹，慢性手湿疹，特应性皮炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CORECTIM® Ointment 0.25%、CORECTIM® Ointment 0.5%、Delgocitinib (JAN/USAN)

+ [12]

靶点

JAK1 x JAK2 x JAK3 x TYK2

作用方式

抑制剂

作用机制

JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)、JAK3抑制剂(酪氨酸蛋白激酶JAK3抑制剂)

治疗领域

免疫系统疾病遗传病与畸形皮肤和肌肉骨骼疾病+ [1]

在研适应症

非在研适应症

原研机构

在研机构

+ [4]

非在研机构-

权益机构

Japan Tobacco, Inc.

Torii Pharmaceutical Co., Ltd.

LEO Pharma A/S

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (2020-01-23),

特应性皮炎

最高研发阶段(中国)申请上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H18N6O

InChIKeyLOWWYYZBZNSPDT-ZBEGNZNMSA-N

CAS号1263774-59-9

关联

40

项与德戈替尼相关的临床试验

NCT07335588

/ Not yet recruiting临床3期

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream in Adult Participants With Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because LS is more likely to affect females compared to males.
The trial is conducted in 2 parts. Part 1 of the trial enrolls female participants with LS and results in the selection of the optimal dose for Part 2. The selected dose will then be evaluated in Part 2, which will enroll both female and male participants. Assessment of efficacy and safety of delgocitinib cream in male participants with LS will be evaluated in a substudy.
For each participant, the trial will last at least 55 weeks and up to 60 weeks.

开始日期2026-05-06

申办/合作机构

Leo Pharma, Inc.

NCT07203274

/ Not yet recruitingN/AIIT

The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch Sensitivity in Healthy Volunteers

It is well known that itch and pain have many communalities in terms of pathways and molecules involved. Therefore, it is very important to investi-gate different substances that work against both pain and itching. The substances delgocitinib and lidocaine have both been shown to relieve various types of pain. We therefore assume that these creams will be also able to relieve itching. The purpose of this trial experiment is therefore to investigate the effect of delgocitinib, lidocaine and their combination on experimentally induced itching.

开始日期2025-12-01

申办/合作机构

University of Aalborg

CTIS2025-523635-19-00

/ Not yet recruiting临床2期IIT

Open-label proof-of-concept trial of topical delgocitinib in patients with facial vitiligo

开始日期2025-11-03

申办/合作机构

Gentofte Hospital

100 项与德戈替尼相关的临床结果

登录后查看更多信息

100 项与德戈替尼相关的转化医学

登录后查看更多信息

100 项与德戈替尼相关的专利（医药）

登录后查看更多信息

133

项与德戈替尼相关的文献（医药）

2026-02-01·PHARMACOLOGICAL RESEARCH

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update

Review

作者: Roskoski, Robert

Because of the dysregulation of protein kinase activity in many neoplastic and inflammatory diseases, protein kinases are among the most significant drug targets in the 21st century. Of the 94 FDA-approved protein kinase inhibitors, ten were approved in 2025. Of these drugs, six target dual specificity protein kinases (MEK1/2), fourteen inhibit protein-serine/threonine kinases, twenty-six block nonreceptor protein-tyrosine kinases, and 48 target receptor protein-tyrosine kinases. Most of these drugs (≈ 80) are prescribed for the management of neoplasms and others are used for the treatment of inflammatory and miscellaneous diseases. Of the 94 FDA-approved agents, about two dozen are used in the treatment of multiple diseases. The following ten drugs received FDA approval in 2025 - avutometinib (inhibiting MEK1/2 in serous ovarian carcinomas), defactinib (blocking FAK in low grade serous ovarian carcinomas), delgocitinib (antagonizing the JAK family in hand eczema), mirdametinib (inhibiting MEK1/2 in type I neurofibromatosis), remibrutinib (blocking BTK in chronic spontaneous urticaria), rilzabrutinib (antagonizing BTK in chronic immune thrombocytopenia), sunvozertinib (blocking mutant exon 21 insertion EGFR NSCLC), taletrectinib (inhibiting mutant ROS1 in NSCLC), vimseltinib (blocking CSF1R in tenosynovial giant cell tumors), and zongertinib (antagonizing mutant HER2 in NSCLC). Ninety of the approved protein kinase blockers are orally bioavailable. This article summarizes the physicochemical properties of all 94 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 45 of the 94 FDA-approved drugs have a least one Lipinski rule of five violation.

2026-02-01·Dermatology and Therapy

Delgocitinib Cream Reduces Itch and Pain in Moderate to Severe Chronic Hand Eczema: Phase 3 DELTA 1 and 2 Pooled Analyses

Article

作者: Plohberger, Ursula ; Schuttelaar, Marie-Louise ; Baranowski, Keith ; Sørensen, Laura ; Worm, Margitta ; Bauer, Andrea

INTRODUCTION:

Itch and pain are two of the most common and burdensome symptoms for moderate to severe Chronic Hand Eczema (CHE). Here, we assess changes in itch/pain in patients with moderate to severe CHE treated with delgocitinib cream 20 mg/g or cream vehicle for 16 weeks.

METHODS:

In a pooled DELTA 1 (NCT04871711)/DELTA 2 (NCT04872101) analysis (delgocitinib [n = 639]; cream vehicle [n = 321]; twice-daily), the Hand Eczema Symptom Diary captured patient-reported itch/pain severity on a numeric rating scale. Changes in itch/pain from baseline were assessed daily during week 1 and weekly from week 1 to 16.

RESULTS:

In delgocitinib-treated patients, a statistically significant least square mean reduction from baseline was observed for itch from day 1 ([delgocitinib cream/cream vehicle] 0.75/0.32; P < 0.001) and pain from day 3 (0.98/0.58; P = 0.001) after the first application. Among patients with ≥ 4-point baseline itch/pain score, a significantly greater percentage of delgocitinib-treated patients achieved ≥ 4-point reduction from week 2 (14.2%/17.3%) versus cream vehicle (6.3%/6.9%; P < 0.001). Reductions were maintained up to week 16 with delgocitinib cream treatment. Delgocitinib cream was well tolerated.

CONCLUSION:

Early onset of itch/pain reduction was observed within week 1 for delgocitinib-treated patients, thereby providing further support of the use and efficacy of delgocitinib cream in adults with moderate to severe CHE.

2026-01-27·CLINICAL AND EXPERIMENTAL DERMATOLOGY

Chronic hand eczema treated with topical delgocitinib cream

Article

作者: Wilson, Charmaine ; Tso, Simon

A patient describes their experience of living with chronic hand eczema.

166

项与德戈替尼相关的新闻（医药）

2026-02-18

·EndPoints

Leo Pharma says it's turned a profit for the first time in seven years

For the first time since 2018, Leo Pharma said it turned a profit last year thanks to new brands on the market and rising sales in the US. The dermatology-focused company collected 2.49 billion Danish krone ($394 million) in net profit for 2025 due to the launch of its chronic hand eczema drug Anzupgo in 10 countries, including the US. It also profited from a licensing deal with Boehringer Ingelheim. CEO Christophe Bourdon told Endpoints News last year that profitability is one of the milestones the company is tracking if it wants to go public . In an interview with Endpoints ahead of its 2025 earnings release on Wednesday, Bourdon said it will be the “shareholders’ decision on if and when to push the button on the IPO.” Currently, the Leo Foundation has a majority stake in Leo Pharma, with Nordic Capital also holding a minority stake after its investment in March 2021. Leo Pharma has been eyeing a potential IPO since at least 2022. It underwent a broad multiyear restructuring to boost its balance sheet. In a bid to boost profitability, the company reshuffled its R&D teams and made sweeping layoffs . These actions seem to be paying off: The last time it turned a profit was in 2018, when it made DKK 1.26 billion ($200 million). Leo Pharma’s profits were down for seven consecutive years due to various factors , including high R&D and restructuring costs, impairment charges, and spending on acquisitions such as the Timber Pharmaceuticals deal in 2023. Bourdon was named CEO in 2022. But Leo Pharma made efforts last year to boost its dermatology product offerings, which drove the business’ revenue up by 12% for 2025 compared to the previous year. The company launched Anzupgo in the US in September and brought Spevigo into its portfolio after inking a licensing deal with Boehringer in July. Spevigo is a monoclonal antibody used to treat generalized pustular psoriasis. Combined revenue for Anzupgo, Spevigo and Adbry increased by 48% for 2025 compared to the year before. Adbry, branded as Adtralza in Europe, is used to treat moderate-to-severe atopic dermatitis. Overall, Leo Pharma pulled in DKK 13.5 billion ($2.1 billion) in revenue for 2025, up 10% compared to 2024. The jump is mainly driven by 35% growth in the US. As for 2026, the company is expecting its revenue to grow between 8% and 11% at constant exchange rates.

IPO财报并购引进/卖出高管变更

2026-02-18

·BioSpace

LEO Pharma Delivers 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin

BALLERUP, Denmark--(BUSINESS WIRE)--In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow. The portfolio was strengthened by the launch of Anzupgo ® in 10 additional markets, including the U.S., as well as the addition of Spevigo ® . The pipeline was advanced through new late‑stage programs and strategic partnerships aimed at accelerating innovation. For 2026, revenue growth is expected to be 8-11% (CER), supporting further improvement in the adjusted EBITDA margin to 16-19%, alongside increased investments in innovation and LEO Pharma’s global platform. Financial highlights LEO Pharma’s revenue increased by 10% at constant exchange rates (CER) and by 8% in DKK to 13,499 million. Revenue growth was led by North America (+35% at CER), with Rest of World (+9% at CER) and Europe (+3% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 12% (CER), driven by the Strategic brands Adtralza ® /Adbry ® , Anzupgo ® , and Spevigo ® , which combined had a revenue increase of 48% (CER), in addition to growth of 2% (CER) for the Established brands. Sales in the Critical Care portfolio declined by 1% (CER), affected by a reversal of sales discounts in the same period last year. Operating profit improved sharply, with adjusted EBITDA reaching DKK 2,107 million in 2025, reflecting a margin of 16% (2024: 7%), excluding the STAT6 partnership upfront payment from Gilead Sciences received in January 2025 and other non-recurring items. The improvement in adjusted EBITDA was driven by sales growth and reduced operating expenses. Net profit for 2025 was DKK 2,489 million (2024: negative DKK 1,776 million), including non-recurring items. Free cash flow was DKK 1,875 million for 2025 (2024: negative DKK 52 million), and net interest-bearing debt was reduced to DKK 9,347 million (2024: DKK 11,115 million). Excluding M&A, free cash flow was DKK 940 million. Innovation highlights Anzupgo ® (delgocitinib) cream was launched in the U.S. in September as the first and only topical pan‑JAK inhibitor for chronic hand eczema, supported by a more than 50% increase in LEO Pharma’s U.S. sales force following FDA approval in July 2025. Spevigo ® (spesolimab), an IL-36RA biologic for generalized pustular psoriasis, joined LEO Pharma’s portfolio on 30 September as its third global, first-in-class brand following a development and commercialization license secured from Boehringer Ingelheim. In 2025, LEO Pharma entered several strategic partnerships to advance innovation, including an agreement with Gilead Sciences for the pre-clinical STAT6 program. The pipeline was expanded with new late stage trials of Anzupgo ® (delgocitinib cream) in adults with palmoplantar pustulosis and lichen sclerosus, as well as the addition of an ongoing Phase 3 trial of Spevigo ® (spesolimab) in pyoderma gangrenosum. 2026 Outlook For 2026, group revenue growth is expected at 8-11% (CER) driven by Anzupgo ® and Spevigo ® . The adjusted EBITDA margin is expected to improve to 16-19%, led by gross margin expansion, offset by higher commercial investments and R&D. "2025 was another year of strong progress for LEO Pharma and a landmark year in our strategic transformation. We expanded our portfolio, delivered strong growth with significantly improved profitability, and formed new partnerships to accelerate innovation. With the ongoing launch of Anzupgo ® and the addition of Spevigo ® , we enter 2026 with strong momentum, committed to making a fundamental difference for patients by further unlocking the potential of our global platform.” CEO Christophe Bourdon. FY 2025 Financial overview (DKK million) FY 2025 FY 2024 Growth Revenue 13,499 12,453 8% Revenue growth at CER 10% 11% N.m. Adjusted EBITDA 2,107 895 135% Adjusted EBITDA margin 16% 7% N.m. Net profit/(loss) for the period 2,489 (1,777) N.m. About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin. For more information, visit Financial highlights and key figures (DKK million) FY 2025 FY 2024 Income statement Revenue 13,499 12,453 Of which dermatology revenue 10,991 10,008 Gross profit 8,240 7,518 Adjusted EBITDA 1 2,107 895 Non-recurring items 1 1,644 (295) EBITDA 1 3,751 600 Operating profit/(loss) (EBIT) 2,279 (1,143) Net financials (566) (814) Profit/(loss) before tax 1,713 (1,957) Net profit/(loss) for the period 2,489 (1,776) Balance sheet Assets 20,445 20,151 Equity 5,262 2,704 Net working capital 2 3,991 3,833 Net interest-bearing debt (NIBD) 3 9,358 11,115 Invested capital 4 14,380 13,637 Cash flow Cash flow from operating activities 1,255 265 Cash flow from investing activities 620 (317) Free cash flow 1,875 (52) Key ratios (%) Revenue growth 8% 9% Revenue growth at CER 1 10% 10% Dermatology revenue growth at CER 12% 12% Gross margin 61% 60% OPEX ratio 57% 70% Adjusted EBITDA margin 1 16% 7% EBITDA margin 1 28% 5% EBIT margin 17% (9)% Effective tax rate (45%) 9% NIBD/Adjusted EBITDA (LTM) 5 4.4 12.4 People Average number of full-time employees (FTE) 4,104 4,184 1 See Note 2 Non-IFRS measures. 2 Net working capital comprises Inventories, Trade receivables and Other receivables less Trade payables and Other payables. 3 The net interest-bearing debt (NIBD) is the interest-bearing liabilities less cash and cash equivalents. 4 Invested capital is calculated as the sum of non-current assets, net working capital and tax receivables less deferred tax liabilities and other non-interest-bearing liabilities. 5 Adjusted EBITDA (LTM) is the adjusted EBITDA in the last 12 months. Contacts For further information please contact: Investor Relations: Christian Boas Ryom, telephone +45 4494 5888 Media: Jeppe Ilkjær, telephone +45 3050 2014

引进/卖出临床3期财报上市批准生物类似药

2026-02-17

·丁香园皮肤时间

2025 皮肤领域年终盘点：特应性皮炎年度进展

近年来，特应性皮炎（AD）的治疗取得了突飞猛进的发展。在丁香园与人卫继续医学教育网携手举办的「2025 皮肤领域年终盘点」上，北京大学人民医院的张建中教授针对 2025 年中国皮肤科在 AD 领域的研究成果与临床应用进行了系统的回顾，咱们一睹为快。图 1 . 张建中教授演讲 01 外用药应用进展值得欣慰的是，在 2024 至 2025 年间，AD 外用药领域取得了突破性进展。我国在 2024 年 11 月率先获批了本维莫德（benvitimod）乳膏用于治疗 AD，审批进度领先于美国。临床试验显示，治疗 8 周后，患者的 EASI 75 达标率达到 54%，皮损完全清除或基本清除（IGA 0/1）的比例达 46%[1]。张建中教授特别指出，跨国临床数据显示，儿童 AD 患者对本维莫德的反应优于成人。中国和日本的儿童Ⅲ期临床研究结果高度一致，有效率分别达到 69% 和 70%[1,2]。除了本维莫德外，还有不少其他的在研药物。张建中教授预计，2026 至 2028 年间，将有不少外用新药陆续在中国上市，这包括三款新型 JAK 抑制剂外用药，它们是来自丹麦利奥的 delgocitinib、恒瑞制药的 SHR0302 和明慧制药的 MHO04 乳膏，以及第二代 PDE4 抑制剂罗氟斯特（roflumilast）。图 2 . 国内 JAK 抑制剂外用治疗 AD 的研发概况（图源讲者 PPT） 02 生物制剂的应用进展张建中教授提到，中国学者在真实世界研究方面表现活跃，生物制剂在临床研究和真实世界证据方面积累了大量数据，涵盖了免疫机制和长期疗效的探讨，尤其强调了度普利尤单抗（dupilumab）和司普奇拜单抗（stapokibart）。研究证实，度普利尤单抗对妊娠期女性及胎儿是安全的，其自然流产率与正常人群相似；此外，证据表明它与淋巴瘤的发生没有关联[3,4]。不过有关免疫漂移的相关研究也值得我们关注[5]。司普奇拜单抗是中国自主研发的生物制剂，研究发现，对司普奇拜单抗快速应答的患者，可以尝试延长给药间隔并维持疗效；此外，它对 6 岁以上儿童的研究结果良好，有望于 2026 年获批儿童适应证[6,7]。 03 新型小分子靶向药应用进展随后，张建中教授指出，JAK 抑制剂等小分子靶向药物在中国的应用日益广泛。以乌帕替尼为例，它在中国的真实世界研究已覆盖超过 20 种疾病领域，包括各类皮肤综合征等，可见这类药物的临床应用广度很高，前景良好。图 3 . 乌帕替尼上市以来皮肤科领域真实世界研究概览（图源讲者 PPT）阿布昔替尼方面，真实世界研究显示，最初接受阿布替尼治疗的队列在瘙痒和皮疹有明显改善，且外周血嗜酸性粒细胞计数、血清 lgE 水平以及 Th1/Th2/Treg 相关细胞因子水平均显著降低[8]。针对艾玛昔替尼中重度 AD Ⅲ 期临床试验显示，艾玛昔替尼 IGA 应答率在 4 mg组为 36.3%，8 mg 组为 42.0%，均显著高于安慰剂组，EASI-75 应答率和瘙痒评分均有显著改善，且 8 mg 剂量在各项疗效指标上均显示出比 4 mg 剂量更高的数值[9]。 04 新靶点药物研发进展在 AD 的新靶点药物研发方面，正向更精准、多效的方向发展。我们用表格的方式进行了总结。表 1 . 特应性皮炎新靶点药物研发进展 05 新推出的 AD 相关指南与共识张建中教授在演讲快结束时提到，2025 年我国发布了多项重要的专家共识与指南，规范了诊疗流程，这包括：《JAK 抑制剂治疗免疫介导炎症性疾病的中国专家共识》：由皮肤科、免疫科、消化科专家共同编写，旨在规范生物制剂在跨学科领域的使用。《特应性皮炎外用治疗与管理专家共识（2025 版）》：全面梳理了传统及新型外用药物的处理方案，为临床医生提供了精准的用药参考。《中国结节性痒疹指南》：由高兴华教授领衔制定并发表，标志着中国 AD 诊疗进一步与国际标准接轨。本次演讲立足国内，聚焦治疗，涵盖了从新型外用药、生物制剂到小分子靶向药物的全面进步。在演讲的最后，张建中教授为我们做了 5 点总结，结束了此次干货满满的年度演讲： 2024/2025 年度是特应性皮炎诊疗高速发展之年我国上市了多款 AD 新药，开展了很多真实世界研究通过研究，积累了外用药、生物制剂和 JAK 抑制剂的应用经验针对 Treg 靶向药物、蛋白降解药、双抗等药物研发正在进行我国推出了多个 AD 相关治疗与管理的指南与共识特别说明 | 本文仅供医疗卫生等专业人士阅读本文审核 | 张建中教授编辑 | 吴丹整理 | 唐教清题图 | 丁香园设计团队参考文献（上下滑动查看） [1] Zhao Y, Wei Z, Feng Y, et al. Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial. Chin Med J (Engl). 2025.. Epub ahead of print. [2] Igarashi A, Tsuji G, Fukasawa S, et al. Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials. J Dermatol. 2024; 51(11): 1404-1413. [3] Sánchez-García V, De-Miguel-Balsa E, Ramos-Rincón JM, Belinchón-Romero I. Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2025; 105: adv41307 [4] Lavin L, Geller S. Cutaneous T cell lymphoma following dupilumab therapy in patients with atopic dermatitis: Clinical review and recommendations. Am J Clin Dermatol. 2025; 26(5): 723-731. [5] Lin TL, Fan YH, Fan KS, et al. Psoriasis risk in patients with atopic dermatitis treated with dupilumab. JAMA Dermatol. 2025; 161(8): 813-821. [6] Zhao Y, Zhang L, Wu L, et al. Long-term stapokibart treatment induces sustained clinical improvements in patients with moderate-to-severe atopic dermatitis. Dermatitis. 2025. Epub ahead of print. [7] Zhao M, Xu Z, Wu L, et al. Safety and efficacy of stapokibart, an anti-IL-4Rα monoclonal antibody, in children aged 6-11 years with moderate-to-severe atopic dermatitis: An open-label, single-arm phase 1b/2a trial. Br J Dermatol. 2025: ljaf455. [8] Li Z, Wang Y, Wu Y, et al. Real-world efficacy and safety of abrocitinib in Chinese atopic dermatitis patients: A single-center prospective study. Allergy. 2025; 80(5): 1417-1427. [9] Zhao Y, Gooderham M, Yang B, et al. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2025; 161(7): 688-697.

100 项与德戈替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11046	-	D11AH	DB16133

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性湿疹	英国	LEO Pharma A/S	2024-11-29
慢性手湿疹	欧盟	LEO Pharma A/S	2024-09-19
慢性手湿疹	冰岛	LEO Pharma A/S	2024-09-19
慢性手湿疹	列支敦士登	LEO Pharma A/S	2024-09-19
慢性手湿疹	挪威	LEO Pharma A/S	2024-09-19
特应性皮炎	日本	Japan Tobacco, Inc.	2020-01-23
特应性皮炎	日本	Shionogi & Co., Ltd.	2020-01-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
硬化萎缩苔癣	临床3期	美国	Leo Pharma, Inc.	2026-02-11
硬化萎缩苔癣	临床3期	加拿大	Leo Pharma, Inc.	2026-02-11
硬化萎缩苔癣	临床3期	法国	Leo Pharma, Inc.	2026-02-11
硬化萎缩苔癣	临床3期	德国	Leo Pharma, Inc.	2026-02-11
硬化萎缩苔癣	临床3期	意大利	Leo Pharma, Inc.	2026-02-11
硬化萎缩苔癣	临床3期	波兰	Leo Pharma, Inc.	2026-02-11
硬化萎缩苔癣	临床3期	西班牙	Leo Pharma, Inc.	2026-02-11
硬化萎缩苔癣	临床3期	英国	Leo Pharma, Inc.	2026-02-11
汗疱疹	临床3期	丹麦	LEO Pharma A/S	2022-01-30
汗疱疹	临床3期	丹麦	Japan Tobacco, Inc.	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05332366 (Pubmed \| J Invest Dermatol)	临床2期	前额纤维化脱发 CXCL9 \| CXCL10 \| IFN-γ	30	Delgocitinib cream	醖選襯餘遞顧鹹衊夢鬱(觸廠夢繭鹽遞窪繭壓鑰) = 選蓋憲獵淵鏇憲醖選構顧鏇醖簾鬱遞衊觸繭衊 (築餘構襯淵網鬱觸鬱製 )	积极	2025-10-01
NCT05486117 (Pubmed \| J Eur Acad Dermatol Venereol)	临床1期	慢性手湿疹	16	Delgocitinib cream 20 mg/g	觸衊願築憲夢鏇壓範鬱(選觸鏇遞鑰廠夢積觸襯) = 範遞廠簾膚鏇襯網廠壓積構繭鹹餘鹽襯網顧簾 (築鏇鏇範積廠衊糧餘範 ) 更多	积极	2025-09-01
NCT04872101 \| NCT04871711 (FDA_CDER) 人工标引	临床3期	慢性手湿疹	960	ANZUPGO (TRIAL 1)	壓蓋廠顧蓋廠製蓋淵壓(窪願獵願壓製鬱窪鬱壓) = 餘繭願餘廠遞簾鹽憲齋窪廠衊膚網製網積壓鹹 (觸鏇蓋顧糧鬱齋鹹蓋鑰 ) 更多	积极	2025-07-23
				Vehicle (TRIAL 1)	壓蓋廠顧蓋廠製蓋淵壓(窪願獵願壓製鬱窪鬱壓) = 餘鹽鹹願膚淵遞繭鑰齋窪廠衊膚網製網積壓鹹 (觸鏇蓋顧糧鬱齋鹹蓋鑰 ) 更多
NCT05355818 (DELTA TEEN, CTgov)	临床3期	慢性手湿疹	98	Delgocitinib (Delgocitinib Cream)	餘襯壓鑰壓選築構網襯 = 簾觸窪觸壓襯廠夢獵蓋簾鬱遞膚餘鹽艱鹽遞廠 (醖壓鏇鹹憲簾簾顧窪窪, 餘獵憲積顧醖構艱鹽鏇 ~ 範窪願襯觸構膚積繭鏇) 更多	-	2025-07-02
				Cream vehicle (Cream Vehicle)	餘襯壓鑰壓選築構網襯 = 鹽遞簾齋顧窪醖鑰構膚簾鬱遞膚餘鹽艱鹽遞廠 (醖壓鏇鹹憲簾簾顧窪窪, 鹽糧蓋繭蓋衊淵夢願餘 ~ 廠窪顧憲餘齋憲遞糧築) 更多
NCT05259722 (DELTA FORCE, Pubmed) 人工标引	临床3期	慢性湿疹	513	delgocitinib cream	選壓網簾壓淵艱獵積壓(願觸觸淵鹹蓋鑰廠選顧) = 簾願糧顧遞憲網獵齋餘窪糧製齋廠廠艱壓顧獵 (繭淵繭淵糧繭鹹鹹醖衊, 3.4) 更多	优效	2025-04-01
				alitretinoin	選壓網簾壓淵艱獵積壓(願觸觸淵鹹蓋鑰廠選顧) = 鹽壓鹽窪鹹觸糧窪鑰壓窪糧製齋廠廠艱壓顧獵 (繭淵繭淵糧繭鹹鹹醖衊, 3.4) 更多
NCT05259722 (DELTA FORCE, CTgov)	临床3期	慢性湿疹	513	Delgocitinib (Delgocitinib Cream 20 mg/g)	鹹製襯窪醖鬱網蓋餘鑰(製網壓醖餘願範顧鏇鬱) = 網膚範積壓糧願膚醖衊遞遞製鏇憲餘鏇艱醖鑰 (積範憲艱簾觸遞願醖糧, 3.37) 更多	-	2025-03-14
				Toctino (Alitretinoin Capsules 30 mg Per Capsule)	鹹製襯窪醖鬱網蓋餘鑰(製網壓醖餘願範顧鏇鬱) = 齋鬱糧繭糧壓鏇願夢觸遞遞製鏇憲餘鏇艱醖鑰 (積範憲艱簾觸遞願醖糧, 3.36) 更多
NCT04872101 (DELTA 2, AAD2025)	临床2期	慢性手湿疹	19	Delgocitinib cream 20 mg/g	獵網顧簾壓膚積壓觸遞(網積膚鹽襯簾範襯餘夢) = 觸衊繭鹽獵鹽窪築選膚構齋築夢艱壓蓋糧醖製 (餘網憲選淵積觸憲選獵 )	积极	2025-03-07
				single oral dose of 1.5 mg delgocitinib	獵網顧簾壓膚積壓觸遞(網積膚鹽襯簾範襯餘夢) = 網遞窪鏇糧願願築廠鏇構齋築夢艱壓蓋糧醖製 (餘網憲選淵積觸憲選獵 )
AAD2025	N/A	慢性手湿疹	1,154	Topical Delgocitinib 20-30 mg/g	衊蓋淵願獵鏇鹽鏇遞襯(衊鹹憲願夢選製獵膚淵) = 鑰選膚淵構願鏇顧鹽糧顧廠築糧願繭網鑰鑰築 (願餘淵憲醖廠艱襯鑰壓 ) 更多	积极	2025-03-07
				Vehicle	衊蓋淵願獵鏇鹽鏇遞襯(衊鹹憲願夢選製獵膚淵) = 顧齋壓積壓襯顧衊鹹鹹顧廠築糧願繭網鑰鑰築 (願餘淵憲醖廠艱襯鑰壓 ) 更多
NCT04949841 (DELTA 3, CTgov)	临床3期	慢性湿疹	801	Delgocitinib	壓鹹廠艱簾觸構願願夢 = 觸膚窪艱窪壓製廠窪獵憲膚築構淵構壓鑰鏇範 (衊艱積顧憲觸鬱積膚選, 鑰餘選淵積獵鹽膚選膚 ~ 憲簾鹹遞觸繭鹹淵構範) 更多	-	2025-01-20
NCT05259722 (BusinessWire) 人工标引	临床3期	慢性湿疹	513	Delgocitinib cream	壓膚獵餘糧築簾顧網簾(齋餘繭繭艱窪顧遞鑰窪) = 壓憲糧壓製願繭襯選獵範夢淵積壓選網築壓範 (憲選膚廠獵構範鏇觸鬱 ) 达到更多	积极	2024-09-25
				Alitretinoin capsules	壓膚獵餘糧築簾顧網簾(齋餘繭繭艱窪顧遞鑰窪) = 窪蓋獵繭蓋獵齋繭簾選範夢淵積壓選網築壓範 (憲選膚廠獵構範鏇觸鬱 ) 达到更多